Pharma merger study shows cost savings don't always reach consumers
An analysis of the 2019 GSK-Pfizer consumer health merger in the Philippines found that while the combined business became cheaper to operate, those savings were not passed on as lower prices. Instead, a major rival's prices rose substantially. The study, published in the Southern Economic Journal, suggests merger efficiencies may not offset competitive harm.
This study adds to a long-running debate in antitrust economics: whether mergers that create operational efficiencies ultimately benefit consumers through lower prices. The 2019 GSK-Pfizer consumer health merger in the Philippines provided a natural test case. Researchers found the combined entity reduced its operating costs, yet retail prices for its products did not fall. Meanwhile, a key competitor raised prices sharply, suggesting the merger may have weakened price competition in the market. The findings, published in the Southern Economic Journal, highlight that cost savings from consolidation do not automatically translate into consumer gains, complicating the case for merger approvals based on efficiency arguments.
This research could influence how regulators evaluate future mergers in consumer goods and pharmaceuticals. If efficiencies rarely reach consumers, then approving deals that reduce competition may lead to higher prices for everyday health products. Patients and households could bear the burden, while rival firms might feel emboldened to raise prices. The study may prompt policymakers to demand stronger evidence of consumer benefits before allowing consolidation, though its single-market focus limits broad conclusions.